ADMA Biologics (ADMA) revenue breakdown
By segment, ADMA BioManufacturing is the largest at 97% of fiscal 2025 revenue, growing 61% a year over 8 years.
By product, Product Revenue is the largest at 100% of fiscal 2022 revenue, growing 91% a year over 2 years.
Revenue by segment
Fiscal years, as ADMA Biologics reports them in its 10-K filings; fiscal 2025 total $510M.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing | $11M | $7M | $22M | $37M | $75M | $144M | $250M | $416M | $493M | 97% |
| Plasma Collection Centers | $12M | $10M | $7M | $5M | $6M | $10M | $8M | $11M | $17M | 3% |
| Corporate | $142,834 | $142,834 | $142,834 | $142,834 | — | — | — | — | — | — |
Revenue by product
Fiscal years, as ADMA Biologics reports them in its 10-K filings; fiscal 2022 total $154M.
| Products | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|
| Product Revenue | $42M | $81M | $154M | 100% |
| License Revenue | $142,834 | $142,834 | $142,834 | 0% |
Revenue by region
Fiscal years, as ADMA Biologics reports them in its 10-K filings; fiscal 2025 total $510M.
| Regions | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| United States | $37M | $71M | $146M | $245M | $410M | $504M | 99% |
| International | $6M | $10M | $8M | $13M | $16M | $6M | 1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ADMA.
Open ADMA in InvestinglyQuestions
Where does ADMA Biologics make its money?
In fiscal 2025, by segment: ADMA BioManufacturing $493M, Plasma Collection Centers $17M.
From ADMA Biologics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.